Fig 1: Loss of endothelial UCP2 leads to persistent increased astrocyte production. A) Confocal immunofluorescence image of S100β + cells in P0 UCP2WT and UCP2ECKO mice. Scale bar, 100 µm. B) Quantification of the number of S100β + cells showing increased S100β + cells in UCP2ECKO mice. **P < 0.01 (mean ± SEM, unpaired two‐tailed Student's t test, n = 5 mice each group). C) Confocal immunofluorescence image of GFAP+ cells in P0 UCP2WT and UCP2ECKO mice. The down is higher magnification images. Scale bars, 100 µm (up), 50 µm (down). D) Quantification of the number of GFAP+ cells showing increased GFAP+ cells in UCP2ECKO mice. ***P < 0.001 (mean ± SEM, unpaired two‐tailed Student's t test, n = 7 each group from 3 independent experiments). E) Western blot analysis of the expression levels of astrocyte marker GFAP and ALDH1L1. β‐actin was detected as loading control. F) Statistics of relative intensity of GFAP and ALDH1L1 showing increased the expression of GFAP+ and ALDH1L1+ cells in P2 UCP2ECKO mice. *P < 0.05 (mean ± SEM, unpaired two‐tailed Student's t test, GFAP n = 3 mice each group; ALDH1L1 n = 4 mice each group). G) Confocal immunofluorescence image of GFAP+ cells in P8 UCP2WT and UCP2ECKO mice. A1, A2, B1, and B2 are higher magnification images. Scale bars, 200 µm (up), 50 µm (down). H) Quantification of the number of GFAP+ cells showing increased GFAP+ cells in UCP2ECKO mice. *P < 0.05 (mean ± SEM, unpaired two‐tailed Student's t test, n = 5 each group from 3 independent experiments). I) Confocal immunofluorescence image of S100β + cells in P8 UCP2WT and UCP2ECKO mice. The down is higher magnification images. Scale bars, 200 µm (up), 50 µm (down). J) Quantification of the number of S100β + cells showing increased S100β + cells in UCP2ECKO mice. **P < 0.01 (mean ± SEM, unpaired two‐tailed Student's t test, UCP2WT n = 5 each group, UCP2ECKO n = 6 each group from 3 independent experiments). Data are represented as means ± SEM. unpaired two‐tailed Student's t test; At least three biological replicates are shown. *P < 0.05. **P < 0.01, ***P < 0.001.
Fig 2: H2A.Z.1 regulates the differentiation of astrocytes in vitro and in vivo. (A and B) Immunofluorescence staining for GFAP and H2A.Z.1 in the cerebral cortex at E16.5, E18.5 and P8. Scale bar, 100 μm. (C) E16.5 NPCs were isolated from the mouse brain cortex and cultured for 1 or 3 days. Double staining for H2A.Z.1 and DAPI, GFAP, Acsbg1 or SOX2 in cultured cells. Scale bar, 50 μm. (D) E16.5 NPCs were infected with lentivirus encoding a control-shRNA (GFP) or a H2A.Z.1-shRNA (H2A.Z.1 KD#1; H2A.Z.1 KD#2) and then cultured in differentiation medium for 3 days. Western blot analysis for Aldh1l1, Acsbg1, GFAP, H2A.Z.1 and H2A expression in cultured NPCs. H2A.Z.1 knockdown inhibits the differentiation of NPCs, while the classic H2A histones are not affected. (E) Quantifications of Aldh1l1, Acsbg1, GFAP and H2A.Z.1 expressions when H2A.Z.1 was knocked down. Data are represented as means ± S.E.M. (n = 3; one-way ANOVA; **P < 0.01, ***P < 0.001). (F) Control-shRNA or H2A.Z.1-shRNA plasmids were injected into the lateral ventricles of E15.5 embryonic brains and electroporated into the mouse cortex. The brains were isolated from newborns (P0) and subsequently immunostained with astrocyte marker GFAP. Scale bar, 100 μm. (G) In the electroporated brain slices, the percentages of GFAP+GFP+ cells among the total GFP-positive cells. Data are represented as means ± S.E.M. (n = 3; one-way ANOVA; **P < 0.01, ***P < 0.001). (H) E16.5 NPCs were infected with lentivirus encoding a control-shRNA or a H2A.Z.1-shRNA and then cultured in differentiation medium for 3 days. The cultured astrocytes were immunostained for GFAP. Scale bar, 100 μm. (I) In the NPCs cultures, the percentages of GFAP+GFP+ cells among the total GFP-positive cells. Data are represented as means ± S.E.M. (n = 3; one-way ANOVA; **P < 0.01, ***P < 0.001).
Fig 3: Evidence of phagocytic astrocytes and microglia following injury. Injured midbrains 24 h post-injury include both astrocytes (D–F) and microglia (J–L) that are positive for N-tubulin-GFP (white arrowheads), as well as for aldh1l1 (astrocytes) or IB4 (microglia); merged fluorescent signal appears white. Magenta (A–F), aldh1l1; Magenta 9 (G–L), IB4; Green, N-Tubulin-GFP; Blue, DAPI. Sham brains (A–C,G–I) contain no more than a few such cells. scale bars, 20 µm.
Fig 4: Deletion of Aldh1l1 in combination with phenformin treatment suppresses Kras-driven lung tumorigenesis. (a) Scheme of the experimental protocol. KrasLA2; Aldh1l1+/+ or KrasLA2; Aldh1l1−/− mice were treated with phenformin (100 mg/kg) or vehicle control by oral administration. Drug was administered once a day, 5 days a week, for 10 weeks from 6 to 16 weeks after birth. (b) Representative photomicrographs of hematoxylin and eosin (H&E) staining (Top), hyperplasia lesion (Middle, black box) and adenoma lesion (Bottom, red box) in mouse lungs harvested 16 weeks after birth. Scale bar = 400 μm. (c) Lungs of mice were analyzed, and all lesions were classified for hyperplasia and adenoma. (d) Representative photomicrographs of cytokeratin 19 staining in mouse lungs harvested 16 weeks after birth. Quantitative analysis of (e) number of tumor nodules and (f) tumor area in mouse lungs 16 weeks after birth. Tumor area (expressed as %) was calculated by dividing the total tumor area by the total area of the lung. p-values were obtained by one-way ANOVA test and are indicated by asterisks (* p < 0.05; ** p < 0.01; *** p < 0.001). (g) Body weight was measured once a week (n = 7).
Fig 5: ALDH1L1 is a target of oncogenic KRAS. (a) Schematic representation of the reporter construct used in the cell-based transduction system. This lentiviral reporter construct expressed firefly luciferase under the control of the ALDH1L1 promoter and Renilla luciferase under the control of the HSV TK promoter. (b) KRAS-mutant NSCLC cells stably expressing the reporter system described in (a) were treated with control or KRAS siRNA. Firefly and Renilla luciferase activities were normalized against the corresponding levels in the sample transfected with control siRNA. Bars show relative luciferase activity (n = 3). (c) KRAS WT NSCLC cells stably expressing the reporter system described in (a) were transfected with control (empty vector), KRAS WT, or KRAS mutant (G12D). Firefly and Renilla luciferase activities were normalized against the corresponding levels in the sample transfected with empty vector. Bars indicate relative luciferase activity (n = 3). (d) In silico prediction of binding sites for transcription factors downstream of KRAS: SP1, transcription factor Sp1; Elk-1, ETS Like-1 transcription factor. (e) Immunohistochemical staining of ALDH1L1 in lungs isolated from KrasLA2 mice at 8, 12, and 16 weeks of age. The scale bar represents 200 mm (** p < 0.01, *** p < 0.001 and **** p < 0.0001).
Supplier Page from Abcam for Anti-ALDH1L1 antibody [3E9] - Astrocyte Marker